Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833136 | 0.75 | — | — | |
| SCHEMBL13520927 | 0.74 | RAB9A (0.30) | RAB9ASMN1; SMN2BRD4BRD2 | |
| SCHEMBL25041109 | 0.74 | ACHE (0.30) | BRD4BRD2 | |
| SCHEMBL14070456 | 0.74 | CRBN (0.36) | SMN1; SMN2BRD4BRD2 | |
| SCHEMBL13389945 | 0.71 | — | — | |
| SCHEMBL4695861 | 0.71 | CRHBP (0.34) | — | |
| SCHEMBL13389917 | 0.71 | BRD4 (0.37) | BRD4BRD2 | |
| SCHEMBL505075 | 0.70 | — | — | |
| SCHEMBL2350200 | 0.69 | — | — | |
| SCHEMBL2301320 | 0.69 | KMT2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA | 2019-09-10 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| EP-2678017-B1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| WO-2012113103-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE S.A. (CH) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116176-A2 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | WO | disclosed |
| US-6762192-B2 | USEFUL IN THERAPY AND PROPHYLAXIS OF EPILEPSY, MIGRAINE, AND OTHER DISORDERS | SMITHKLINE BEECHUM P.L.C. (GB) | 2004-07-13 | — | — | US | disclosed |
| EP-1084122-B1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-6538136-B1 | Cyclization of ketone, aldehyde, and primary amine in presence of acid catalyst | ELI LILLY AND COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | SMITHKLINE BEECHAM P.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6410555-B1 | ANTIEPILEPTIC AGENTS; HEADACHES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| EP-1196382-A2 | PREPARATION OF SUBSTITUTED PIPERIDIN-4-ONES | ELI LILLY AND COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1084122-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2001-03-21 | — | — | EP | disclosed |
| WO-2001000577-A2 | PREPARATION OF SUBSTITUTED PIPERIDIN-4-ONES | ELI LILLY AND COMPANY (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000007993-A1 | SUBSTITUTED ISOQUINOLEINES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999065903-A1 | TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143029-A1 | Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity | CNR1, SCN1B, CNR2 | RAB9A 4276/4885SMN1; SMN2 953/4885BRD4 851/4885 |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | UTS2R, GPR119, GHSR | RAB9A 2808/4885SMN1; SMN2 2413/4885BRD4 4175/4885 |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | RAB9A 2808/4885SMN1; SMN2 2413/4885BRD4 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.